NAD replenishment with nicotinamide mononucleotide protects blood–brain barrier integrity and attenuates delayed tissue plasminogen activator‐induced haemorrhagic transformation after cerebral ischaemia

BACKGROUND AND PURPOSE: Tissue plasminogen activator (tPA) is the only approved pharmacological therapy for acute brain ischaemia; however, a major limitation of tPA is the haemorrhagic transformation that follows tPA treatment. Here, we determined whether nicotinamide mononucleotide (NMN), a key in...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Br J Pharmacol
Prif Awduron: Wei, Chun‐Chun, Kong, Yuan‐Yuan, Hua, Xia, Li, Guo‐Qiang, Zheng, Si‐Li, Cheng, Ming‐He, Wang, Pei, Miao, Chao‐Yu
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: John Wiley and Sons Inc. 2017
Pynciau:
Research Papers
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC5647191/
https://ncbi.nlm.nih.gov/pubmed/28812311
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/bph.13979
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg